Accumulated evidence indicated that deletion of liver-specific AMPK exacerbates liver injury and hepatic steatosis in NASH mice (30, 31), and activation of AMPK signaling alleviates the progression of NAFLD/NASH in mice (32, 33, 34). Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.